2007;100:781 6. 188. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291:2328 34. 189. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast- induced nephropathy in primary angioplasty. N Engl J Med. 2006;354: 2773 82. 190. Thiele H, Hildebrand L, Schirdewahn C, et al. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: the LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. J Am Coll Cardiol. 2010;55:2201 9. 191. McCullough PA, Adam A, Becker CR, et al. Risk prediction of contrast- induced nephropathy. Am J Cardiol. 2006;98:27K 36K. 192. Coca SG, Krumholz HM, Garg AX, et al. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006;296:1377 84. 193. Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Cir- culation. 2010;121:357 65. 194. American Heart Association. Get With the Guidelines. Available at: http://www.americanheart.org/GWTG. Accessed March 20, 2012. 195. ASSENT-4 PCI Investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment ele- vation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006;367:569 78. 196. Bonow RO, Masoudi FA, Rumsfeld JS, et al. ACC/AHA classification of care metrics: performance measures and quality metrics: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Circulation. 2008;118:2662 6. 197. Henry TD, Sharkey SW, Burke MN, et al. 